| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop …
Over the last 12 months, insiders at Estrella Immunopharma, Inc. have bought $0 and sold $0 worth of Estrella Immunopharma, Inc. stock.
On average, over the past 5 years, insiders at Estrella Immunopharma, Inc. have bought $22.34B and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $1,330 was made by Xu Jiandong (Chief Financial Officer) on 2025‑10‑07.
| 2025-10-07 | Xu Jiandong | Chief Financial Officer | 1,000 0.0028% | $1.33 | $1,330 | -9.52% | ||
| 2025-09-22 | Xu Jiandong | Chief Financial Officer | 1,000 0.0027% | $1.16 | $1,160 | 0.00% | ||
| 2025-09-11 | Xu Jiandong | Chief Financial Officer | 100 0.0003% | $1.04 | $104 | +12.50% | ||
| 2022-03-04 | Li Jianwei | Co-Chief Executive Officer | 141,970 – | $314,700.00 | $44.68B | +0.90% |
| Xu Jiandong | Chief Financial Officer | 265488 0.6103% | $110,973.98 | 3 | 0 | +0.99% |
$1,993,425 | 46 | -21.91% | $13.95M | |
$931,435 | 28 | 16.31% | $24.8M | |
$226,127 | 22 | -27.62% | $21.96M | |
$114,619,342 | 20 | -7.41% | $16.39M | |
$352,389 | 18 | 9.66% | $17.82M |
| Increased Positions | 14 | +175% | 357,595 | +48.12% |
| Decreased Positions | 3 | -37.5% | 51,176 | -6.89% |
| New Positions | 6 | New | 131,779 | New |
| Sold Out Positions | 2 | Sold Out | 4,016 | Sold Out |
| Total Postitions | 19 | +137.5% | 1M | +41.23% |
| Vanguard Group Inc | $583.00 | 1.11% | 419,711 | +136,868 | +48.39% | 2025-09-30 |
| Geode Capital Management, Llc | $141.00 | 0.27% | 101,490 | -1,847 | -1.79% | 2025-09-30 |
| Ubs Group Ag | $70.00 | 0.13% | 50,347 | -22,426 | -30.82% | 2025-09-30 |
| Citadel Advisors Llc | $70.00 | 0.13% | 50,122 | -34 | -0.07% | 2025-09-30 |
| Atw Spac Management Llc | $56.00 | 0.11% | 40,000 | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $33.00 | 0.06% | 24,084 | -7,323 | -23.32% | 2025-09-30 |
| State Street Corp | $31.00 | 0.06% | 22,352 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $15.00 | 0.03% | 10,689 | +10,689 | New | 2025-09-30 |
| Xtx Topco Ltd | $14.00 | 0.03% | 10,373 | +10,373 | New | 2025-09-30 |
| Maso Capital Partners Ltd | $14.00 | 0.03% | 10,000 | 0 | 0% | 2025-09-30 |